Statin discontinuation in high-risk patients: A systematic review of the evidence

Current Pharmaceutical Design

Volumn 17, Issue 33, 2011, Pages 3669-3689

  Gomez Sandoval, Yessica Haydee ^a   Braganza, Michael V ^a   Daskalopoulou, Stella S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cardiovascular disease; Cerebrovascular disease; Discontinuation; High risk; Non adherence; Perioperative; Primary prevention; Secondary prevention; Statins

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT COMPLIANCE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SECONDARY PREVENTION; SUBSTANCE WITHDRAWAL SYNDROME; SURGICAL PROCEDURES, OPERATIVE;

EID: 82055192332     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798220891     Document Type: Article

References (113)

1. Cardiovascular diseases (CVDs). [World Health Organization Website]: World Health Organization; 2011 [updated January 2011; cited 2011 March 24]; Fact sheet No317]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/#.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001; 285(19): 2486-97.
3. Wood D. Established and emerging cardiovascular risk factors. Am Heart J 2001; 141(2 Suppl): S49-57.
4. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166(21): 2307-13.
5. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008; 4(2): 341-53.
6. Arshad A, Mandava A, Kamath G, Musat D. Sudden cardiac death and the role of medical therapy. Prog Cardiovasc Dis 2008; 50(6): 420-38.
7. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 2008; 121(1): 24-33.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001-9.
9. Sever PS, Poulter NR, Dahlof B, Wedel H. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96(5A): 39F-44F.
10. Kwak BR, Mach F. Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001; 21(8): 1256-8.
11. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest 2003; 124(2): 740-3.
12. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol 1999; 31(1): 5-14.
13. Hansen PR. Inflammatory alterations in the myocardial microcirculation. J Mol Cell Cardiol 1998; 30(12): 2555-9.
14. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33(1): 234-41.
15. Bohm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, van Veldhuisen DJ. Heart failure and statins-why do we need a clinical trial? Z Kardiol 2005; 94(4): 223-30.
16. Strey CH, Young JM, Molyneux SL, et al. Endotheliumameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005; 179(1): 201-6.
17. Urbich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int 2005; 67(5): 1672-6.
18. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102(25): 3104-10.
19. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005; 178(2): 359-63.
20. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43(3): 580-94.
21. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999; 43(3): 650-7.
22. Laufs U, Liao JK. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol 2003; 23(2): 156-7.
23. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111(5): 390-400.
24. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19(6): 540-56.
25. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308(6925): 367-72.
26. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332(17): 1125-31.
27. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother 1993; 27(9 Suppl): S1-24.
28. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007; 99(4): 530-4.
29. Jackevicius CA, Mamdami M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA-J Am Med Assoc 2002; 288(4): 462-7.
30. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164(4): 208-11.
31. [Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 2009; 122(10): 961.e7-13.
32. Shepherd J, Cobbe SM, Lorimer AR, et al. Compliance and adverse event withdrawal: their impact on the west of Scotland Coronary Prevention Study. Eur Heart J 1997; 18(11): 1718-24.
33. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. J Am Coll Cardiol 1999; 33(4): 909-15.
34. Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care 2010; 16(6): 459-66.
35. Blackburn DE, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005; 25(8): 1035-43.
36. Corrao G, Conti V, Merlino L, Catapano AL, Mancia G. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010; 32(2): 300-10.
37. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: The case of cholesterol-lowering therapy. Am J Manag Care 2006; 12(1): 21-8.
38. Perreault S, Dragomir A, Blais L, Berard A, Lalonde L, White M. Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008; 66(5): 706-16.
39. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009; 65(10): 1013-24.
40. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007; 63(6): 698-708.
41. Saito Y, Shirai K, Sasaki N, Shinomiya M, Yoshida S, Committee of the Chiba Lipid Intervention Program S. Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study. J Atheroscler Thromb 2002; 9(2): 99-108.
42. Penning-van Beest FJA, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJP, Herings RMC. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007; 28(2): 154-9.
43. Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med 2009; 122(7): 647-55.
44. Risselada R, Straatman H, van Kooten F, Dippel DWJ, van der Lugt A, Niessen WJ, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke 2009; 40(8): 2887-92.
45. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009; 169(3): 260-8.
46. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166(17): 1836-41.
47. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006; 6: 48.
48. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105(12): 1446-52.
49. Heeschen C, Hamm CW, Laufs U, Bohm M, Snapinn S, White HD. Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003; 107(3): e27.
50. Klungel OH, Heckbert SR, de Boer A, et al. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother 2002; 36(5): 751-7.
51. Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherenceassociated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010; 103(6-7): 363-75.
52. Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008; 66(1): 110-6.
53. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88(3): 229-33.
54. Lesaffre E, Kocmanova D, Lemos PA, Disco CMC, Serruys PW. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003; 25(9): 2431-47.
55. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140(11): 857-66.
56. McGowan MP, Treating to New Target Study G. There is no evidence for an increase in acute coronary syndromes after shortterm abrupt discontinuation of statins in stable cardiac patients. Circulation 2004; 110(16): 2333-5.
57. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke - A controlled randomized study. Neurology 2007; 69(9): 904-10.
58. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction - National Registry of Myocardial Infarction. Arch Intern Med 2004; 164(19): 2162-8.
59. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96(5): 611-6.
60. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166(17): 1842-7.
61. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008; 29(17): 2083-91.
62. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155(4): 772-9.
63. McGinnis BD, Olson KL, Delate TMA, Stolcpart RS. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manag Care 2009; 15(10): 689-95.
64. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007; 116(7): 737-44.
65. Huan Loh P, Windram JD, Tin L, et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. Am Heart J 2007; 153(4): 537-44.
66. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. Jama 2007; 297(2): 177-86.
67. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38(10): 2652-7.
68. Schouten O, Hoeks SE, Welten G, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007; 100(2): 316-20.
69. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007; 104(6): 1326-33, table of contents.
70. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006; 132(2): 392-400.
71. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 2006; 26(9): 1288-96.
72. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 2006; 37(10): 2640-3.
73. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008; 7(6): 717-25.
74. Pineda A, Cubeddu LX. Statin rebound or withdrawal syndrome: does it exist? Curr Atheroscler Rep 2011; 13(1): 23-30.
75. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009; 10(18): 2973-85.
76. Biccard BM. A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (nonsurgical) patients. Anaesthesia 2008; 63(1): 52-64.
77. Daskalopoulou SS. When statin therapy stops: implications for the patient. Curr Opin Cardiol 2009; 24(5): 454-60.
78. Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005; 25(9): 1093-110.
79. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006; 7(1): 31-5.
80. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004; 35(11 Suppl 1): 2708-11.
81. Jones PJH. Statin rebound effect? Journal of Laboratory and Clinical Medicine 2003; 141 (4): 235-6.
82. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 2007; 9(3): 58.
83. Papadopoulos S, Cook AM. You can withdraw from that? The effects of abrupt discontinuation of medications. Orthopedics 2006; 29(5): 413-7.
84. Rodriguez-Yanez M, Davalos A, Castillo J. Withdrawal from statins: implications for secondary stroke prevention and acute treatment. Int j 2008; 3(2): 85-7.
85. Stone NJ. Stopping statins. Circulation 2004; 110(16): 2280-2.
86. De Vera MA, Choi H, Abrahamowicz M, Kopec J, Goycochea- Robles MV, Lacaille D. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011; 70(6): 1020-4.
87. Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ 2011; 342: d12.
88. Lai WT, Lee KT, Chu CS, et al. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. Int J Cardiol 2005; 98(3): 459-64.
89. Sposito AC, Carvalho LS, Cintra RM, et al. Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis 2009; 207(1): 191-4.
90. Lee KT, Lai WT, Chu CS, et al. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004; 102(3): 166-70.
91. Li JJ, Li YS, Chu JM, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta 2006; 366(1-2): 269-73.
92. van der Harst P, Asselbergs FW, Hillege HL, et al. Effect of withdrawal of pravastatin therapy on C-reactive protein and lowdensity lipoprotein cholesterol. Am J Cardiol 2007; 100(10): 1548-51.
93. Huang CY, Wu TC, Lin WT, et al. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Eur J Clin Invest 2006; 36(2): 76-84.
94. Li JJ, Fang CH, Chen MZ, Chen X, Lee SW. Activation of nuclear factor-kappaB and correlation with elevated plasma c-reactive protein in patients with unstable angina. Heart Lung Circ 2004; 13(2): 173-8.
95. Maseri A. Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon. N Engl J Med 1997; 336(14): 1014-6.
96. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138(5 Pt 2): S419-20.
97. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
98. Yip HK, Youssef AA, Chua S, et al. Re-elevation of highsensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting. Int Heart J 2006; 47(4): 501-9.
99. Puccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyperactivity after statin treatment discontinuation. Thrombosis and Haemostasis 2003; 90(3): 476-82.
100. Puccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90(3): 476-82.
101. Taneva E, Borucki K, Wiens L, et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006; 97(7): 1002-6.
102. Westphal, S., C. Abletshauser, et al. Fluvastatin treatment and withdrawal: effects on endothelial function. Angiology 2008; 59(5): 613-8.
103. Westphal S, Abletshauser C, Luley C. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction. Coron Artery Dis 2009; 20(1): 81-5.
104. Chen H, Ren JY, Xing Y, et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: A dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 2009; 131(3): 313-20.
105. Chen H, Ikeda U, Shimpo M, Shimada K. Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res 2000; 23(2): 187-92.
106. Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34(2): 551-7.
107. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88(11): 1306-7.
108. Kataoka C, Egashira K, Inoue S, et al. Important role of Rhokinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39(2): 245-50.
109. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59(3): 646-54.
110. Aviram M, Rosenblat M, Etzioni A, Levy R. Activation of NADPH oxidase required for macrophage-mediated oxidation of lowdensity lipoprotein. Metabolism 1996; 45(9): 1069-79.
111. Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J 1994; 8(15): 1279-84.
112. Daskalopoulou SS, Doonan RJ, Mikhailidis DP. Undertreatment of hypercholesterolemia. Curr Med Res Opin; 26(2): 439-43.
113. Phillips B, Roberts C, Rudolph AE, Morant S, Aziz F, O'Regan CP. Switching statins: The impact on patient outcomes. Br J Cardiol 2007; 14 (5): 280-5.